Furthermore, TRIM36 was identified as a suppressor of FOXA2 by inducing its K48‐linked polyubiquitination, which may have a therapeutic benefit in CRC patients with FOXA2 overexpression. The gene discussed is FOXA2; the disease is colorectal carcinoma.